Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 28, 2018
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (AKBA) and Keryx Biopharmaceuticals, Inc. (KERX) today announced that the companies signed, and the boards of directors of ...
June 28, 2018
InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
JENA, Germany, June 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the ...
June 28, 2018
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
TEL-AVIV, Israel and RALEIGH, N.C., June 28, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical ...
June 28, 2018
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
BURLINGTON, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...
June 28, 2018
Entera Bio Ltd. Announces Pricing of Initial Public Offering
JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX) (NASDAQ:ENTXW), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered ...
June 27, 2018
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on ...
June 27, 2018
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
NEW YORK, June 27, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, ...
June 27, 2018
Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and ...
June 27, 2018
Kitov to Host Business Update Conference Call on Monday, July 2
Tel Aviv, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today announced that it will ...
June 26, 2018
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
Basel, Switzerland, June 26, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that the first patient has been dosed in the phase 2a expansion part ...
June 26, 2018
DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
VANCOUVER, British Columbia and MENLO PARK, Calif., June 26, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on ...
June 26, 2018
BrainStorm Provides Update on "Right to Try" Policy
NEW YORK and PETACH TIKVA, Israel, June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today ...
June 26, 2018
ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug ...
June 26, 2018
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
TEL AVIV, Israel, June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments ...
June 25, 2018
BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
NEW YORK and PETACH TIKVAH, Israel, June 25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
June 25, 2018
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today ...
June 25, 2018
Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
DUBLIN, Ireland, June 25, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies ...
June 25, 2018
Genkyotex Expands License Agreement for Vaxiclase Platform with Serum Institute of India
ARCHAMPS, France--(BUSINESS WIRE)--Regulatory News: Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces that ...
June 25, 2018
Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018
Amsterdam, The Netherlands, June 25, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company ...
June 25, 2018
ArQule Added to the Russell 2000® Index
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (ARQL) today announced that it has been added to the Russell 2000® Index, a subset of the Russell 3000® Index, effective as ...
Page 62 of 150